BenevolentAI S.A. (BAI.AS)
EUR 0.4
(-4.31%)
EUR 0.4
(-4.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -63.31 Million GBP | 61.38% |
| 2022 | -163.92 Million GBP | -89.55% |
| 2021 | -86.48 Million GBP | -56.21% |
| 2020 | -55.36 Million GBP | -14.32% |
| 2019 | -48.43 Million GBP | -80.17% |
| 2018 | -26.88 Million GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -63.31 Million GBP | 61.38% |
| 2022 FY | -163.92 Million GBP | -89.55% |
| 2021 FY | -86.48 Million GBP | -56.21% |
| 2020 FY | -55.36 Million GBP | -14.32% |
| 2019 FY | -48.43 Million GBP | -80.17% |
| 2018 FY | -26.88 Million GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -1699.801% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 57.143% |
| Adocia SA | -21.16 Million EUR | -199.201% |
| Aelis Farma SA | -5.07 Million EUR | -1146.889% |
| Biophytis S.A. | -17.02 Million EUR | -271.884% |
| Advicenne S.A. | -7.03 Million EUR | -800.54% |
| genOway Société anonyme | 1.56 Million EUR | 4139.169% |
| IntegraGen SA | -171.39 Thousand EUR | -36841.289% |
| Medesis Pharma S.A. | -3.95 Million EUR | -1499.12% |
| Neovacs S.A. | -8.74 Million EUR | -624.165% |
| NFL Biosciences SA | -3.74 Million EUR | -1590.493% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 80077.011% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -1896.785% |
| Sensorion SA | -22.06 Million EUR | -186.977% |
| Theranexus Société Anonyme | -6.82 Million EUR | -827.321% |
| TME Pharma N.V. | -6.73 Million EUR | -839.979% |
| Valbiotis SA | -7.36 Million EUR | -759.351% |
| TheraVet SA | -1.57 Million EUR | -3931.115% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -211.232% |
| argenx SE | -272.91 Million EUR | 76.8% |
| BioSenic S.A. | -28.77 Million EUR | -120.019% |
| Celyad Oncology SA | -8.44 Million EUR | -649.491% |
| DBV Technologies S.A. | -67.26 Million EUR | 5.875% |
| Galapagos NV | 211.69 Million EUR | 129.909% |
| Genfit S.A. | -28.89 Million EUR | -119.135% |
| GeNeuro SA | -14.75 Million EUR | -329.064% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -311.684% |
| Innate Pharma S.A. | -7.57 Million EUR | -736.42% |
| Inventiva S.A. | -110.42 Million EUR | 42.661% |
| MaaT Pharma SA | -19.71 Million EUR | -221.129% |
| MedinCell S.A. | -25.03 Million EUR | -152.884% |
| Nanobiotix S.A. | -39.7 Million EUR | -59.489% |
| Onward Medical N.V. | -36.18 Million EUR | -75.001% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -1788.401% |
| OSE Immunotherapeutics SA | -23 Million EUR | -175.255% |
| Oxurion NV | -18.96 Million EUR | -233.792% |
| Pharming Group N.V. | -9.75 Million EUR | -548.967% |
| Poxel S.A. | -35.09 Million EUR | -80.442% |
| GenSight Biologics S.A. | -26.22 Million EUR | -141.484% |
| Transgene SA | -22.32 Million EUR | -183.577% |
| Financière de Tubize SA | 88.15 Million EUR | 171.828% |
| UCB SA | 343 Million EUR | 118.46% |
| Valneva SE | -101.42 Million EUR | 37.575% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -123.403% |